This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 20 and 80
years old
The phase for this study is not defined.
Show me locations

The purpose

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques. Therefore, in this study the investigators intend to compare the effect of ezetimibe monotherapy or ezetimibe plus statin combination therapy on the atherosclerosis regression using FDG-PET.

Provided treatments

  • Drug: Ezetrol (Ezetimibe)
  • Drug: Vytorin (Ezetimibe + Simvastatin)
Tris trial is registered with FDA with number: NCT00926055. The sponsor of the trial is Korea University and it is looking for 0 volunteers for the current phase.
Official trial title:
Effects on Atherosclerosis Regression of Ezetimibe Monotherapy or Ezetimibe Plus Simvastatin Combination Therapy: Evaluation by Fluorodeoxyglucose Positron Emission Tomography